Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients

Michelle Petri

doi:10.1007/s11926-010-0141-y

Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients

Curr Rheumatol Rep. 2011 Feb;13(1):77-80. doi: 10.1007/s11926-010-0141-y.

Author

Michelle Petri¹

Affiliation

¹ Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA. mpetri@jhmi.edu

PMID: 20978875
DOI: 10.1007/s11926-010-0141-y

Abstract

Hydroxychloroquine is used extensively in the treatment of systemic lupus erythematosus, not only for its benefit for cutaneous and musculoskeletal lupus, but also for its role in preventing flares, preventing renal and central nervous system lupus, and improving survival rates. Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus. This article reviews its possible role as an antithrombotic drug in the general population, in systemic lupus erythematosus, and in patients with antiphospholipid antibodies.

Publication types

Review

MeSH terms

Antibodies, Antiphospholipid / immunology
Antiphospholipid Syndrome / complications*
Antiphospholipid Syndrome / drug therapy
Antiphospholipid Syndrome / immunology
Enzyme Inhibitors / therapeutic use*
Humans
Hydroxychloroquine / therapeutic use*
Lupus Erythematosus, Systemic / complications*
Lupus Erythematosus, Systemic / drug therapy
Lupus Erythematosus, Systemic / immunology
Thrombosis / etiology
Thrombosis / immunology
Thrombosis / prevention & control*

Substances

Antibodies, Antiphospholipid
Enzyme Inhibitors
Hydroxychloroquine